In contrast, post-treatment differences were driven by the closer proximity of PD-1+ CD4+ T cells and tumor cells in responders (Supplementary Fig. 4d, see red arrow), consistent with the increased immune activation gene score in responders relative to nonresponders (Fig. 2g). The gene discussed is PDCD1; the disease is neoplasm.